Falagas M E, Siakavellas E
Hygeia Hospital, 4 Er. Stavrou Str., 151 23, Athens, Greece.
Int J Antimicrob Agents. 2000 Jun;15(1):1-9. doi: 10.1016/s0924-8579(99)00164-8.
Recent basic and clinical research efforts have shed more light on the taxonomy, microbiology, epidemiology, antimicrobial susceptibility and treatment of Bacteroides, Prevotella, and Porphyromonas species. Of all anaerobic bacteria, Bacteroides is the most frequently isolated pathogen from clinical specimens, including blood. Bacteroides, Prevotella and/or Porphyromonas species have been isolated from clinical specimens in cases of infection from almost all anatomic sites. Several multicentre surveys have documented an alarming gradual increase of resistance rates of Bacteroides, Prevotella and Porphyromonas species worldwide. Antimicrobial agents active against >99% of clinical isolates of Bacteroides are metronidazole, chloramphenicol and carbapenems. Agents active against 95-99% of Bacteroides fragilis isolates are the beta-lactam/beta-lactamase inhibitor combinations. B. fragilis group species other than B. fragilis are more likely to be resistant to beta-lactam/beta-lactamase inhibitor combinations than B. fragilis.
近期的基础研究和临床研究工作,使人们对拟杆菌属、普雷沃菌属和卟啉单胞菌属菌种的分类学、微生物学、流行病学、抗菌药物敏感性及治疗等方面有了更深入的了解。在所有厌氧细菌中,拟杆菌是临床标本(包括血液)中最常分离出的病原体。从几乎所有解剖部位感染病例的临床标本中都分离出了拟杆菌属、普雷沃菌属和/或卟啉单胞菌属菌种。多项多中心调查记录了全球范围内拟杆菌属、普雷沃菌属和卟啉单胞菌属菌种耐药率令人担忧的逐渐上升情况。对超过99%的拟杆菌临床分离株有效的抗菌药物有甲硝唑、氯霉素和碳青霉烯类。对95% - 99%的脆弱拟杆菌分离株有效的药物是β-内酰胺/β-内酰胺酶抑制剂联合制剂。除脆弱拟杆菌外的其他脆弱拟杆菌群菌种,比脆弱拟杆菌更易对β-内酰胺/β-内酰胺酶抑制剂联合制剂耐药。